[1] Sugano K, Tack J, Kuipers EJ,et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut,2015,64(9):1353-1367.
[2] Cover TL,Peek JM.Diet,microbial virulence,and Helicobacter pylori-induced gastric cancer[J]. Gut Microbes, 2013, 4(6):482-493.
[3] Araújo-Filho I,Brandao-Neto J,Pinheiro LA,et al.Prevalence of Helicobacter pylori infection in advanced gastric carcinoma[J]. Arq Gastroenterol,2006,43(4):288-292.
[4] 中华医学会消化病学分会幽门螺杆菌学组. 幽门螺杆菌胃炎京都全球共识研讨会纪要[J].中华消化杂志,2016,36(1):53-57.
[5] Alakkari A, Zullo A, O'Connor HJ. Helicobacter pylori and nonmalignant diseases[J]. Helicobacter, 2011, 16(Suppl1):33-37.
[6] Fock KM,Graham DY, Malfertheiner P. Helicobacter pylori research:historical insights and future directions[J].Nat Rev Gastroenterol Hepatol,2013,10(8):495-500.
[7] 池肇春.站在新的高度,做好幽门螺旋杆菌感染的防治[J].世界华人消化杂志,2016,24(16):2454-2459.
[8] 李世通,杨兵. 幽门螺杆菌流行病学及耐药性研究现状[J]. 临床医药实践,2016,25(1):53-55.
[9] 张万岱,胡伏莲,萧树东,等. 中国自然人群幽门螺杆菌感染的流行病学调查[J]. 现代消化及介入诊疗,2010, 15(5):265-270.
[10] 祝雯雯,傅爽,孙雯,等. 幽门螺杆菌在人工模拟环境中生存状况的研究[J]. 中国卫生检验杂志,2013,23(3):641-643.
[11] Dorji D, Dendup T, Malaty HM, et al. Epidemiology of Helicobacter pylori in Bhutan:the role of environment and Geographic location[J]. Helicobacter, 2014, 19(1):69-73.
[12] Eusebi LH,Zagari RM,Bazzoli F. Epidemiology of Helicobacter pylori infection[J]. Helicobacter,2014,19(Suppl1):38-40.
[13] Fernández-Tilapa G, Axinecuilteco-Hilera J, Giono-Cerezo S, et al. vacA genotypes in oral cavity and Helicobacter pylori seropositivity among adults without dyspepsia[J]. Med Oral Patol Oral Cir Bucal,2011,16(2):e175-e180.
[14] 刘文忠."幽门螺杆菌胃炎京都全球共识"解读[J].胃肠病学, 2015,20(8):449-455.
[15] Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan[J].J Gastroenterol,2014,49(1):1-8.
[16] Herrero R,Park JY,Forman D.The fight against gastric cancer-the IARC Working Group report[J].Best Pract ResClin Gastroenterol,2014,28(6):1107-1114.
[17] Ding Z,Zhao S,Gong S,et al.Prevalence and risk factors of Helicobacter pylori infection in asymptomatic Chinese children:a prospective,cross-sectional,population-based study[J].Aliment Pharmacol Ther,2015,42(8):1019-1026.
[18] 郭景,徐樨巍. 儿童幽门螺杆菌感染治疗中的难点问题与高耐药幽门螺杆菌根除措施[J].中国实用儿科杂志,2016, 31(7):509-512.
[19] 孙盼盼,刘莉,平智广,等. 不同地区癌症发病分布特征及聚类分析[J].中国癌症杂志,2016,26(6):499-507.
[20] 梅成义,孙树怀.内镜在慢性萎缩性胃炎诊断中的应用[J].中外医疗,2015,23:181-183.
[21] Dixon MF, Genta RM, Yardley JH, et al.Classification and grading of gastritis.The updated sydney system.International Workshop on the Histopathology of Gastritis, Houston 1994[J].Am J Surg Pathol,1996, 20(10):1161-1181.
[22] 张建坤. 慢性胃炎内镜和病理诊断的临床研究[J].中外医学研究,2016,14(19):147-148.
[23] Capelle LG,de Vries AC,Haringsma J,et al.The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis[J].Gastrointest Endosc,2010,71(7):1150-1158.
[24] Cho SJ,Choi IJ,KooK MC,et al.Staging of intestinal-and diffuse-type gastric cancers with the OLGA and OLGIM staging systems[J].Aliment Pharmacol Ther,2013,38(10):1292-1302.
[25] 刘文忠,谢勇, 成虹,等. 第四次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学, 2012, 17(10):618-625.
[26] 徐小青,孙钦娟,廖静贤,等.含铋剂和克拉霉素的四联根除方案在幽门螺杆菌一线治疗中的作用[J].胃肠病学,2012,17(1):5-9.
[27] 刘雪芳,马岚青. 幽门螺旋杆菌对克拉霉素、甲硝唑、左氧氟沙星耐药的研究进展[J]. 胃肠病学和肝病学杂志,2016, 25(1):101-104.
[28] 凌赵起. 含铋剂四联疗法根除老年人幽门螺杆菌感染疗效观察[J]. 福建医药杂志, 2012, 34(1):106-107.
[29] Ford AC, Malfertheiner P, Giguere M, et al. Adverse events with bismuth salts for Helicobacter pylori eradication:Systematic review and meta-analysis[J]. World J Gastroenterol,2008,14(48):7361-7370
[30] Eichler I.The bismuth-encephalopathy-a new pathologicalsyndrome(author's transl)[J].Wien Klin Wochenschr,1979,91(9):314-320.
[31] Serfontein WJ,Mekel R. Bismuth toxicity in man ii. Review of bismuth blood and urine levels in patients after administration of therapeutic bismuth formulations in relation to the problem of bismuth toxicity in man[J]. Res Commun Chem Pathol Pharmacol, 1979, 26(2):391-411.
[32] 王珏磊,刘星宇,聂燕,等. 对铋剂在临床应用利弊的思考[J].中华内科杂志,2012,51(12):932-934.
[33] 张维,陆红. 含铋剂的根除幽门螺杆菌方案在我国应用的经验与建议[J]. 中华消化杂志,2014,9(34):646-648.
[34] 程其娇,本刚,张琳,等.国内序贯疗法对比铋剂四联疗法补救根除幽门螺杆菌感染的Meta分析[J].安徽医药,2016,20(11):2132-2138.
[35] 麻瑞娟,吴静,周永宁. 肠道微生态失衡与非酒精性脂肪肝病的关系[J]. 临床肝胆病杂志,2015,31(1):127-129. |
